ArticleDiscover oncology2025
Serum urate levels and colorectal cancer risk: a prospective cohort study in of the UK biobank and a Mendelian randomization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum urate is the most abundant antioxidant molecule in human blood and may play a role in cancer prevention. However, the association between serum urate levels and colorectal cancer (CRC) risk remains inconclusive, with the underlying causal mechanisms still undefined.
methodsIn the UK Biobank (UKB) cohort, we investigated the prospective association between serum urate levels and the risk of CRC. We used Cox proportional hazards models to estimate the multivariable hazard ratios (HR) for CRC. Subgroup analyses were performed based on anatomical subsite and sex. Additionally, two-sample Mendelian randomization (MR) analysis was conducted to assess the potential causal effect of genetically determined urate levels on CRC risk.
resultsDuring a median follow-up of 11.58 years, 1960 CRC events were recorded among 180,480 participants without baseline CRC in the UKB. Higher urate levels were associated with a decreased risk of CRC (HR = 0.85, 95% CI: 0.72-0.99, P = 0.038). Moreover, the association between urate levels and CRC risk varied by anatomical subsite and sex. Higher urate levels were associated with a decreased risk of colon cancer in the overall population (HR = 0.79, 95% CI: 0.65-0.96, P = 0.015) and colon cancer in female (HR = 0.66, 95% CI: 0.50-0.87, P = 0.003), but not with rectal cancer or CRC in male. MR results supported a causal relationship between serum urate and CRC risk, with higher serum urate levels corresponding to a lower risk of CRC.
conclusionsIn this study, higher urate levels were associated with a reduced risk of CRC, and MR analysis supported a potential causal relationship between urate levels and CRC risk. However, further studies are needed to confirm causality and to investigate the potential subsite-specific effects of urate on CRC development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.